[Lutetium 177 PSMA in patients with prostate cancer]

Coelli J, Perelli L, Bardach A, Colaci C, Alfie V, Ciapponi A, Augustovski F, García Martí S, Alcaraz A, Pichon-Riviere A
Record ID 32018004401
Original Title: 177-Lutecio PSMA en pacientes con cáncer de próstata
Authors' recommendations: No evidence about the use of Lu-177 PSMA in patients with castration-resistant prostate cancer receiving first or second line therapy has been found. Moderate-quality evidence suggests that the use of Lu-177 PSMA versus placebo in patients with PSMA-positive castration-resistant prostate cancer who progressed to at least two previous lines of treatment, improves overall survival, progression-free survival, reduces the PSA values and symptomatic skeletal events when added to standard treatment, compared to placebo. Low-quality evidence suggests that the use of Lu-177 PSMA would be more efficacious in reducing the PSA value, with a lower incidence of Grade 3-4 adverse events when compared with cabazitaxel as third line. The use of this radiopharmaceutical product has not been approved by the National Administration of Medicines, Food and Medical Devices (ANMAT) for this indication. It has not been approved by the United States Food and Drug Administration or the European Medicine Agency either. In clinical practice guidelines from the main international societies consulted, the use of Lu-177 PSMA is limited to experimental purposes. None of the public or private funders from high-income countries covers its use and its coverage is not mentioned in countries of the region. The sale price for this radiopharmaceutical product could not be found; local or international economic evaluations about its cost-effectiveness or budget impact could not be found either.
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Prostatic Neoplasms
  • Radiopharmaceuticals
  • Lutetium
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.